Anebulo Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

6 Months Ended

Dec. 31, 2022

Note 4. Accrued Expenses

Accrued expenses consisted of the following:

Schedule of Accrued Expenses

	December 31, 2022		June 30, 2022
Accrued research and development	$	699,990	$	105,980
Accrued payroll related expenses		295,107		25,723
Accrued other		30,750		-
Total accrued expenses	$	1,025,847	$	131,703